We are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Our MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain-penetrant to treat central nervous system ...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001701541-26-000009 | EDGAR | 100K words |
| 2025-03-06 | 2024-12-31 | 0001701541-25-000016 | EDGAR | — |
| 2024-03-12 | 2023-12-31 | 0001701541-24-000011 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0001701541-23-000020 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0001701541-22-000007 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001701541-21-000018 | EDGAR | — |
| 2020-03-24 | 2019-12-31 | 0001701541-20-000009 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001701541-25-000039 | EDGAR | 26K words |
| 2025-08-07 | 2025-06-30 | 0001701541-25-000030 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001701541-25-000022 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0001701541-24-000042 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001701541-24-000030 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001701541-24-000022 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001701541-23-000047 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001701541-23-000041 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001701541-23-000032 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001701541-22-000037 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001701541-22-000029 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001701541-22-000018 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-16 | 0001701541-26-000008 | EDGAR | 2K words |
| 2025-12-03 | 0001104659-25-117975 | EDGAR | — |
| 2025-11-06 | 0001701541-25-000038 | EDGAR | — |
| 2025-08-07 | 0001701541-25-000029 | EDGAR | — |
| 2025-06-12 | 0001104659-25-058893 | EDGAR | — |
| 2025-05-12 | 0001701541-25-000021 | EDGAR | — |
| 2025-03-19 | 0001104659-25-025338 | EDGAR | — |
| 2025-03-06 | 0001701541-25-000014 | EDGAR | — |
| 2024-11-05 | 0001701541-24-000040 | EDGAR | — |
| 2024-10-07 | 0001104659-24-106676 | EDGAR | — |
93 total filings indexed. 64 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001701541 |
| Ticker | BDTX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.blackdiamondtherapeutics.com |
| Listed | 2020-01-30 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report